Disease · EFO_1001515
ovarian endometrioid carcinoma
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. ovarian endometrioid carcinoma. Diseases, record EFO_1001515. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/EFO_1001515
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Name
- ovarian endometrioid carcinoma
- Open Targets ID
- EFO_1001515
- Highest stage of its drugs
- Phase 2, for 1 of its 3 drugs, from ClinicalTrials.gov
Source Open Targets
Drugs3
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| TAZEMETOSTAT | CHEMBL3414621 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| TUVUSERTIB | CHEMBL5314933 | Small molecule | Phase 1 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| ZEN-3694 | CHEMBL6068600 | Small molecule | Phase 1 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
Targets1
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes |
|---|---|---|---|---|---|
| EZH2 | Histone-lysine N-methyltransferase EZH2 | 1 | Histone-lysine N-methyltransferase EZH2 inhibitor | Phase 2 | https://conductscience.org/library/genes/2146 |
Source Drugs and targets
Trials2
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03348631 | Tazemetostat in Treating Patients With Recurrent Ovarian or Endometrial Cancer | Phase 2 | 62 | 2025-03-06 | Recurrent Endometrial Endometrioid Adenocarcinoma, Recurrent Malignant Uterine Corpus Neoplasm, Recurrent Ovarian Carcinoma, Recurrent Ovarian Clear Cell Adenocarcinoma, Recurrent Ovarian Endometrioid Adenocarcinoma | TAZEMETOSTAT | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT05950464 | Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer | Phase 1 | 65 | Recurrent Endometrial Carcinoma, Recurrent Endometrial Clear Cell Adenocarcinoma, Recurrent Endometrial Endometrioid Adenocarcinoma, Recurrent Endometrial Low Grade Endometrioid Adenocarcinoma, Recurrent Ovarian Clear Cell Adenocarcinoma, Recurrent Ovarian Endometrioid Adenocarcinoma, Recurrent Ovarian High Grade Serous Adenocarcinoma, Recurrent Ovarian Low Grade Endometrioid Adenocarcinoma, Recurrent Platinum-Resistant Ovarian Carcinoma | TUVUSERTIB, ZEN-3694 | Open Targets' reading of its record | ClinicalTrials.gov |
Comparisons in its trials3
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Arm I: Treatment (Tazemetostat) in Endometrial Cancer Patients vs Arm II: Treatment (Tazemetostat) Ovarian in Cancer Patients: Number of Patients With a Grade 3 (or Higher) Adverse Events | 6 of 16 | 20 of 42 | 58 | NCT03348631 | Trial comparisons |
| Arm I: Treatment (Tazemetostat) in Endometrial Cancer Patients vs Arm II: Treatment (Tazemetostat) Ovarian in Cancer Patients: deaths from any cause | 11 of 16 | 28 of 42 | 58 | NCT03348631 | Trial comparisons |
| Arm I: Treatment (Tazemetostat) in Endometrial Cancer Patients vs Arm II: Treatment (Tazemetostat) Ovarian in Cancer Patients: serious adverse events | 3 of 16 | 12 of 42 | 58 | NCT03348631 | Trial comparisons |
Papers from its trials0
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
None in this release.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/EFO_1001515
GET https://conductscience.org/api/diseases/v1/EFO_1001515/drugs